Nucleic acid drug for treatment of allergic disease

Abstract

This invention provides double-stranded (ds) RNA capable of suppressing the expression of STAT6 related to allergic diseases mediated by Th2-type cytokines via RNA interference and a pharmaceutical composition for prevention or treatment of allergic diseases comprising such dsRNA. Such dsRNA is a double-stranded RNA (dsRNA) molecule targeting mRNA of the STAT6 gene composed of (a) or (b): (a) a sense strand identical to a sequence having 15 to 50 continuous nucleotides in the STAT6 gene sequence represented by SEQ ID NO: 1 or 3 and an antisense strand comprising a nucleotide sequence complementary to the nucleotide sequence of the sense strand; or (b) a sense strand comprising a sequence derived from the sequence comprising 15 to 50 continuous nucleotides of the STAT6 gene sequence represented by SEQ ID NO: 1 or 3 by deletion, substitution, or addition of 1 or several nucleotides and capable of hybridizing to the STAT6 gene and an antisense strand comprising a nucleotide sequence complementary to the nucleotide sequence of the sense strand.

Dependencies are inferred from the claim text.